[New administration modalities for radiotherapy in lung cancer].
Much progress has been made in recent years in administration modalities for radiotherapy for lung cancer. Exposure time to external irradiation was the first parameter to be modified: hyperfractionated radiotherapy, hyperfractionated accelerated radiotherapy with or without concomitant irradiation, synchronous or asynchronous protocols, split course radiotherapy. Radiosensitizing agents have also been the subject of much research: radiosensitization of hypoxic cells, modifiers of the biological response, concomitant radiochemotherapy. The main drugs used are 5-fluorouracil, platinum salts, etoposide, hydroxyurea, taxanes, topotecan, vinorelbin, and gemcitabine. Outcome with these combinations is discussed, both for non-small-cell and small-cell lung cancer. 3D conformational radiotherapy can enable increased dosing in the tumoral target while better preserving healthy tissues. High dose endoluminal brachytherapy is used particularly as a palliative treatment for bronchial obstructions or as curative treatment for weakly infiltrative small endoluminal tumors.
Touboul
E
E
Service d'Oncologie-Radiothérapie, Centre des Tumeurs de l'hôpital Tenon, 4 rue de la Chine, 75020 Paris, France.
Deniaud-Alexandre
E
E
Pereira
R
R
Deluen
F
F
D000970:Antineoplastic Agents / Q000008:administration & dosage; D001918:Brachytherapy; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy / Q000532:radiotherapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000532:radiotherapy*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000532:radiotherapy; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D020266:Radiotherapy, Conformal
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents